Jeremey Levin

443 total citations
23 papers, 357 citations indexed

About

Jeremey Levin is a scholar working on Oncology, Surgery and Molecular Biology. According to data from OpenAlex, Jeremey Levin has authored 23 papers receiving a total of 357 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 8 papers in Surgery and 5 papers in Molecular Biology. Recurrent topics in Jeremey Levin's work include Nausea and vomiting management (8 papers), Cancer Treatment and Pharmacology (8 papers) and Colorectal Cancer Treatments and Studies (6 papers). Jeremey Levin is often cited by papers focused on Nausea and vomiting management (8 papers), Cancer Treatment and Pharmacology (8 papers) and Colorectal Cancer Treatments and Studies (6 papers). Jeremey Levin collaborates with scholars based in United States, Canada and United Kingdom. Jeremey Levin's co-authors include Stephen Lane, Joseph Treat, John Hohneker, Steven M. Grunberg, Chao Huang, Mark W. Russo, Richard L. Schilsky, Jørn Herrstedt, Deborah K. Armstrong and Mark Allen O’Rourke and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Annals of Oncology.

In The Last Decade

Jeremey Levin

22 papers receiving 342 citations

Peers

Countries citing papers authored by Jeremey Levin

Since Specialization

Citations

This map shows the geographic impact of Jeremey Levin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeremey Levin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeremey Levin more than expected).

Fields of papers citing papers by Jeremey Levin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeremey Levin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeremey Levin. The network helps show where Jeremey Levin may publish in the future.

Co-authorship network of co-authors of Jeremey Levin

This figure shows the co-authorship network connecting the top 25 collaborators of Jeremey Levin. A scholar is included among the top collaborators of Jeremey Levin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeremey Levin. Jeremey Levin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Whole brain radiation therapy (WBRT) with or without oral topotecan (TPT) in patients (pts) with non-small cell lung cancer (NSCLC) with brain metastases: Final analysis of an open-label phase III study. 2013 ·Journal of Clinical Oncology ·Rodryg Ramlau, Jacek Jassem, Zsolt Pápai-Székely, Pierre Chabot, Philippe Legenne, Jeremey Levin, (unknown), Stephen Lane, John J. Brennan, (unknown), Paul Wissel, Philip Bonomi	3
2	Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, active-controlled, two arm, parallel group study 2011 ·Supportive Care in Cancer ·Paul J. Hesketh, Oliver Wright, Gerardo Rosati, Mark W. Russo, Jeremey Levin, Stephen Lane, Vladimir Moiseyenko, Pierre Dubé, М. В. Копп, Anatoly Makhson	26
3	Phase II Study to Evaluate the Safety and Efficacy of the Oral Neurokinin-1 Receptor Antagonist Casopitant (GW679769) Administered with Ondansetron for the Prevention of Postoperative and Postdischarge Nausea and Vomiting in High-risk Patients 2010 ·Anesthesiology ·Neil Singla, Sonia Singla, Frances Chung, Demetrios J. Kutsogiannis, (unknown), Stephen Lane, Jeremey Levin, Brendan M. Johnson, Joseph V. Pergolizzi	29
4	Phase 2 trial results with the novel neurokinin‐1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy‐induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy 2009 ·Cancer ·Wichit Arpornwirat, István Albert, Vincent Hansen, Jeremey Levin, Rajesh Bandekar, Steven M. Grunberg	21
5	Phase III Trial of Casopitant, a Novel Neurokinin-1 Receptor Antagonist, for the Prevention of Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy 2009 ·Journal of Clinical Oncology ·Jørn Herrstedt, (unknown), (unknown), Zeba Aziz, Fausto Roila, Simon Van Belle, Mark W. Russo, Jeremey Levin, (unknown), Mary Guckert, Steven M. Grunberg	60
6	Safety and efficacy of the novel antiemetic neurokinin-1 (NK-1) receptor antagonist, casopitant, in women with breast cancer (BC) receiving moderately emetogenic chemotherapy (MEC) – subgroup analysis from a randomized, double-blind, placebo-controlled phase II trial 2008 ·European Journal of Cancer Supplements ·Jørn Herrstedt, Wichit Arpornwirat, István Albert, Vincent Hansen, Rajesh Bandekar, Jeremey Levin, Steven M. Grunberg	2
7	Hematologic Safety and Tolerability of Topotecan in Recurrent Ovarian Cancer and Small Cell Lung Cancer: An Integrated Analysis 2005 ·The Oncologist ·Deborah K. Armstrong, David R. Spriggs, Jeremey Levin, (unknown), Stephen Lane	26
8	Topotecan in the Treatment of Relapsed Small Cell Lung Cancer Patients with Poor Performance Status 2004 ·The Oncologist ·Joseph Treat, Chao Huang, Stephen Lane, Jeremey Levin	36
9	Association of topotecan with improved performance status (PS) in relapsed small cell lung cancer (SCLC) patients with poor PS at baseline 2004 ·Journal of Clinical Oncology ·Jeremey Levin, Rogério Lilenbaum, Gregory A. Masters, Stephen Lane, Joseph Treat	1
10	A randomized phase III trial (389): Oral topotecan/cisplatin (TC) vs IV etoposide/cisplatin (PE) as treatment for chemotherapy-naïve patients (pts) with extensive disease small cell lung cancer (ED-SCLC): Interim tolerability results 2004 ·Journal of Clinical Oncology ·John R. Eckardt, Joachim von Pawel, G. Manikhas, Zsolt Pápai, Antoaneta Tomova, Valentina Tzekova, T. Crofts, (unknown), Jeremey Levin, G. Ross	2
11	Association of topotecan with improved performance status (PS) in relapsed small cell lung cancer (SCLC) patients with poor PS at baseline 2004 ·Journal of Clinical Oncology ·Jeremey Levin, Rogério Lilenbaum, Gregory A. Masters, Stephen Lane, Joseph Treat	2
12	Oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma 2002 ·Annals of Oncology ·Al B. Benson, Edith P. Mitchell, Neil Abramson, Barbara Klencke, Paul S. Ritch, (unknown), (unknown), Tab Bonny, Jeremey Levin, John Hohneker	12
13	Multicenter Phase II Study of a 28-Day Regimen of Orally Administered Eniluracil and Fluorouracil in the Treatment of Patients With Anthracycline- and Taxane-Resistant Advanced Breast Cancer 2002 ·Journal of Clinical Oncology ·Edgardo Rivera, Linda Sutton, Bruce Colwell, Mark L. Graham, Debra Frye, Matthew C. Somerville, (unknown), (unknown), Jeremey Levin, Gabriel N. Hortobágyi	14
14	Randomized, Open-Label, Phase III Study of a 28-Day Oral Regimen of Eniluracil Plus Fluorouracil Versus Intravenous Fluorouracil Plus Leucovorin as First-Line Therapy in Patients With Metastatic/Advanced Colorectal Cancer 2002 ·Journal of Clinical Oncology ·Richard L. Schilsky, Jeremey Levin, William H. West, A. Wong, Bruce Colwell, Michael P. Thirlwell, Rafat Ansari, William N. Bell, (unknown), (unknown), Paul V. McGuirt, Richard Pazdur	32
15	Clinical Development of Eniluracil/Fluorouracil: an Oral Treatment for Patients with Solid Tumors 2000 ·Investigational New Drugs ·Jeremey Levin, John Hohneker	6
16	A multicenter phase II study of a five-day regimen of oral 5-fluorouracil plus eniluracil with or without leucovorin in patients with metastatic colorectal cancer 2000 ·Annals of Oncology ·Richard L. Schilsky, Ronald M. Bukowski, Howard A. Burris, Howard S. Höchster, Mark Allen O’Rourke, J. Gerard Wall, Sridhar Mani, Tab Bonny, Jeremey Levin, John Hohneker	23
17	Multicenter Phase II Study to Evaluate a 28-Day Regimen of Oral Fluorouracil Plus Eniluracil in the Treatment of Patients With Previously Untreated Metastatic Colorectal Cancer 2000 ·Journal of Clinical Oncology ·Sridhar Mani, Howard S. Höchster, Thomas Beck, (unknown), Mark Allen O’Rourke, Charles H. Weaver, William N. Bell, Robin White, (unknown), Jeremey Levin, John Hohneker, Richard L. Schilsky, Jacob J. Lokich	35
18	The role of paclitaxel in the treatment of head and neck cancer. 1995 ·PubMed ·Everett E. Vokes, Daniel J. Haraf, Kerstin Stenson, Roger Stupp, (unknown), Jeremey Levin, Ralph R. Weichselbaum	16
19	DNA damage in isolated hamster and rat pancreas cells by pancreatic carcinogens 1984 ·Chemico-Biological Interactions ·Jeremey Levin, Benette Phillips, Zafar Iqbal	4
20	Gastric carcinoma and other malignancies in patients with chronic myelogenous leukemia. Case report and review of the literature, with particular reference to young adults. 1980 ·PubMed ·(unknown), (unknown), Jeremey Levin	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact